Created after a breakthrough discovery in protein research, TriMed Research, Inc. is a joint venture of the University of Nebraska Medical Center, UNeMed Corporation and Tridelta Development, Ltd. TriMed Research's mission is to research and commercially develop therapeutic products, primarily related to the company's patented discovery of the mammary gland protein designated as MAA.
Because synthetic versions of the MAA protein are shown to be bioactive and able to initiate protective processes in the intestine, this discovery may significantly reduce bacterial and viral gastro-intestinal infections in humans and animals.
The discovery of MAA offers a wide variety of potential applications including:
Prevention of life-threatening diseases
experienced by premature infants;
Reduction of infectious diarrhea among
herd animals and possibly bovine mastitis;
Reduction of the debilitating side-effects
of cancer treatments; and
Prevention of "travelers' diarrhea."
